Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer.
Fedor V MoiseyenkoEkatherina Sh KuliginaAlbina S ZhabinaSergey A BelukhinTatiana A LaidusAleksandr S MartianovKirill A ZagorodnevTatyana N SokolovaSvetlana A ChuinyshenaMaksim M KholmatovElizaveta V ArtemievaEkaterina O StepanovaTatiana N ShuginovaNikita M VolkovGrigoriy A YanusEvgeny N ImyanitovPublished in: International journal of clinical oncology (2022)
Comparison of concentration of EGFR-mutated ctDNA at base-line and at 48 h after the start of therapy is predictive for the duration of TKI efficacy.